Table 1.

MDM2 deregulations in various hematological malignancies.

Hematological malignancy	MDM2 deregulation	References
ALL	overexpression	Zhou et al., 1995, 2000; Gu et al., 2008; Zhu et al., 2008
AML	overexpression	Faderl et al., 2000; Kojima et al., 2005; Reis et al., 2016
CLL	overexpression	Haidar et al., 1997; Isin et al., 2012
CML		Trotta et al., 2003; Carter et al., 2015
HL	amplification	Kupper et al., 2001
NHL	overexpression	Pagnano et al., 2001
MCL	amplification, overexpression	Solenthaler et al., 2002; Hernandez et al., 2005
BL	overexpression	Wilda et al., 2004
BCL	overexpression	Riley et al., 2016
DLBCL	overexpression	Davies et al., 2005
MM	overexpression	Teoh et al., 1997; Kryukov et al., 2013; Teoh et al., 2014

ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; HL, Hodgkin’s lymphoma; NHL, non-Hodgkin’s lymphoma; MCL, mantle cell lymphoma; BL, Burkitt’s lymphoma; BCL, B-cell lymphoma; DLBCL, diffuse large B-cell lymphoma; MM, multiple myeloma.